xanomeline-trospium
NDA- Indications
- schizophrenia, Alzheimer's disease psychosis, Bipolar I disorder, Alzheimer's disease agitation
Company intelligence / Profile preview
Karuna Therapeutics
Boston, Massachusetts, USAkaruna-pharmaceuticals.squarespace.com ↗
- Ownership
- Public · KRTX
- Development stage
- NDA
01
Overview
KarXT has demonstrated strong efficacy across multiple Phase III trials for schizophrenia with differentiated safety/tolerability profile versus standard antipsychotics. The NDA for adult schizophrenia was accepted by the FDA with potential approval expected late September 2024. Additional registrational trials are ongoing for adjunctive use in schizophrenia and psychosis in Alzheimer’s disease.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (notably muscarinic receptor modulators such as xanomeline-trospium)TRPC4/5 inhibitors
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaboration with PsychoGenics on KAR–501; previously partnered/inlicensed from Goldfinch Bio estate for KAR–2618
04
Financials
- Market cap
- $12.6B
- Total revenue
- $0
- Enterprise value
- $11.4B
Beyond the preview
Go deeper on Karuna Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Karuna Therapeutics.